EASL 2017 Clinical Practice Guidelines on the management of
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionq European Association for the Study of the Liver⇑ Summary Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration This Clinical Prac-
Expert Presentation Delivered by: Seng Gee Lim, MD Teerha
• EASL-recommended treatments for treatment-naïve patients without cirrhosis are: – Sofosbuvir + daclatasvir (12 – 24 weeks) – Sofosbuvir/velpatasvir (12 weeks) • Shorter treatment duration could enhance patient adherence and access to treatment Foster Graham R, et al Abstract #GS-007, EASL 2017
Expert Presentation Delivered by: Funmilayo Lesi Hailemichael
Data collection as of Mar 1 2017 Representation from 40 US states and DC Majority of care in community practice Metric Academic Community Total Patients 338 1489 1827 Physicians 111 652 763 Curry Michael, et al Abstract #PS-102, EASL 2017
EASL Highlights 2017 - Virology Education BV
Murray, EASL 2017, PS-101 Open-label study of LDV/SOF (45 mg/ 200 mg) fixed dose combination tablet (once daily) ± RBV (15 mg/kg/day up to 1400 mg/day) for 12 or 24 weeks in children aged 6
Best of EASL 2017: Non-Viral Liver Diseases
Best of EASL 2017: Non-Viral Liver Diseases John M Vierling, MD, FACP, FAASLD Professor of Medicine and Surgery Chief of Hepatology Director of Advanced Liver Therapies Baylor College of Medicine Baylor-St Luke’s Medical Center
HBV Update from EASL 2017 - British HIV Association
Agarwal, EASL 2017, FRI-153; Brunetto, EASL 2017 Two phase 3, randomized, double-blind studies Primary Endpoint* Baseline Wk 144Wk 48 Wk 384 TAF 25mg TDF 300mg 1 Open-label Double-blind TAF 25 mg Study 108 HBeAg- (N=425) Study 110 HBeAg+ (N=873) Wk 96
Role of endoscopy in primary sclerosing cholangitis: European
17 EASL/ESGE recommend that cholangiocarcinoma (CCA) should be suspected in any patient with worsening choles-tasis, weight loss, raised serum CA19-9, and/or new or pro-gressive dominant stricture, particularly with an associated enhancing mass lesion Strong recommendation, moderate quality evidence 19 ESGE/EASL recommend ductal sampling
EASL Clinical Practice Guidelines: Liver transplantation
EASL Clinical Practice Guidelines: Liver transplantationq European Association for the Study of the Liver⇑ Introduction The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy Calne in Cambridge in 1968 [1], only one year after the first successful human liver transplantation
Endpoints and New Targets for Curing Hepatitis B
Gilmore S, et al EASL 2017, Amsterdam #SAT-160 AIM: To characterize the relationship between the PD effect (increase in H3K4
Update in the Management of Chronic Hepatitis B
EASL 2017 HBeAg+ no cirrhosis HBeAg seroconversion and UD HBV DNA at least 1 year after HBeAg seroconversion Preferably at least 3 years of consolidation therapy
[PDF] easl 2016 guidelines
[PDF] charte des droits de l'homme et du citoyen
[PDF] interpretation des marqueurs de l'hepatite b
[PDF] serologie hepatite b vaccination
[PDF] les lignes imaginaires de la terre
[PDF] serologie hepatite b interpretation
[PDF] hepatite b anticorps anti hbs positif
[PDF] serologie hepatite b negatif
[PDF] serologie hepatite b pdf
[PDF] serologie hepatite b et c
[PDF] serologie hepatite c
[PDF] qu'est ce que l'hépatite c
[PDF] séance d'arts visuels cycle 3
[PDF] hepatite b contamination salive